Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

NCT03674411 is registered in ClinicalTrials.gov with Masonic Cancer Center, University of Minnesota as lead sponsor.

NCT NCT03674411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03674411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Lead sponsor
Masonic Cancer Center, University of Minnesota
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 2, 2019
Completion date
December 1, 2026
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, acute myeloid leukemia, biphenotypic/undifferentiated leukemia, burkitt lymphoma, chronic myelogenous leukemia, hodgkin lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, myelodysplasia, relapsed large cell lymphoma, relapsed t-cell lymphoma